Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey M Conroy

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
BMC Medical Informatics and Decision Making|January 20, 2019
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencingGrace K Dy, Mary K Nesline, Antonios Papanicolau-Sengos, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancerCarl D Morrison, Pengyuan Liu, Anna Woloszynska-Read, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical TrialLinda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
BMC Medical Informatics and Decision Making|January 20, 2019
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencingGrace K Dy, Mary K Nesline, Antonios Papanicolau-Sengos, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 29, 2014
Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancerCarl D Morrison, Pengyuan Liu, Anna Woloszynska-Read, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical TrialLinda K Zane, Laura M Yee, Ting-Chia Chang, et al.
Pageof 7